Commercial Sales Leadership Program
About the job
- A bachelor's or graduate degree in any major, with graduation between December 2025 and May 2027.
- Demonstrated interest in sales.
- Legal authorization to work in the United States.
- Willingness to travel and relocate multiple times across the United States, including a rotation in Milwaukee, Wisconsin.
- Ability to meet the program's geographic flexibility and accept a post-program placement based on business needs.
- Complete a two-year rotational sales and leadership training program comprising three rotations of six, seven, and eleven months.
- Complete commercial skills and techniques training.
- Complete specialized modality and product training.
- Manage territories and engage with customers.
- Manage sales funnels and conduct prospecting.
- Optimize inside-sales techniques.
- Perform project management.
- Complete self-study modules, digital-tool training, mentored on-the-job training, and headquarters-sponsored training.
- Learn the technical aspects of an assigned modality and prepare for an off-program commercial role.
- Genuine interest in a commercial career within healthcare technology.
- Motivation to learn capital-equipment sales, diagnostic-pharmaceutical selling, and customer-centric solution selling.
- Curiosity about medical technology, patient care, and the healthcare ecosystem.
- Leadership demonstrated through campus involvement, athletics, work experience, community initiatives, or entrepreneurial pursuits.
- Ability to influence without authority and mobilize teams around common goals.
- Aspiration to grow into future leadership roles.
- Ability to overcome adversity, persist through setbacks, and maintain high performance in challenging environments.
- Strong work ethic and personal accountability.
- Competitive spirit balanced with humility and openness to feedback.
- High emotional intelligence and ability to build trust quickly, listen deeply, and engage authentically with customers and teammates.
- Strong interpersonal skills and comfort presenting to diverse audiences.
- Inclusive mindset and willingness to collaborate.
- Strong academic foundation with a GPA of 3.0 or above, plus ability to digest complex information and translate it into actionable insights.
- Previous internship experience or other professional or leadership experience.
- Data-driven decision-making, strong analytical skills, and ability to communicate insights clearly.
- Willingness to relocate multiple times across the United States during the 24-month program.
- Flexibility and openness to accepting a post-program placement based on business needs.
- Comfort navigating ambiguity and thriving in a fast-paced, dynamic environment.
About the company
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 orders rose 11.1%, and backlog hit a record $23.9 billion.
- Duke Health and Queen's Health Systems will pilot CareIntellect for Operations in 2026.
- AsiaMedic deployed MR31 in Singapore, proving international demand for GE's deep-learning MRI tools.
What critics are saying
- Memorial Sloan Kettering sued GE HealthCare on June 1, 2026, over MotionFree patents.
- Patient Care Solutions revenue fell 13.5% in Q2 2026, and management reviews a sale.
- CFO Jay Saccaro resigned July 21, 2026, weakening execution during a segment turnaround.
What makes GE Healthcare unique
- GE HealthCare's Photonova Spectra won FDA, Japan, and CE clearance in 2026.
- CareIntellect for Operations embeds proprietary AI into hospital workflows, not generic dashboards.
- Vivid Explorer 1, Advanced 1, and Focus 1 cover premium-to-midmarket cardiac imaging.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.
GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.
GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.
Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.